The role of osteoanabolic agents in the management of patients with osteoporosis

Postgrad Med. 2022 Aug;134(6):541-551. doi: 10.1080/00325481.2022.2069582. Epub 2022 May 30.


Reducing fracture risk is the objective of osteoporosis treatment. Bone-forming osteoporosis drugs increase bone mass, restore bone microarchitecture, and reduce fracture risk more effectively than oral bisphosphonates, providing strong justification for the use of these agents as the initial therapy or after anti-remodeling agents in patients at very high risk of fracture. At the end of a 12-to-24-month course of osteoanabolic therapy, transitioning to a potent anti-remodeling agent maintains and enhances the treatment benefit. This review describes the clinical applications of osteoanabolic therapy for osteoporosis.

Keywords: Osteoporosis; abaloparatide; osteoanabolic; romosozumab; sequence; teriparatide.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Bone Density
  • Bone Density Conservation Agents* / pharmacology
  • Bone Density Conservation Agents* / therapeutic use
  • Humans
  • Osteoporosis* / drug therapy
  • Parathyroid Hormone-Related Protein / adverse effects
  • Teriparatide / pharmacology


  • Antibodies, Monoclonal
  • Bone Density Conservation Agents
  • Parathyroid Hormone-Related Protein
  • Teriparatide